Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Content from other channels on our network

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

Yarra Valley Water to report net zero operational emissions

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification

Nestlé launches on-pack date-labelling pilot to help tackle food waste

Handling the protein powder boom: engineering solutions for powder processing

Seafood safety researcher awarded at NZIFST Food Industry Awards

Blade innovation reduces the cost of slicing and dicing

Hygienic Design in Practice: Supporting Modern Food Production

Daniel Wyner appointed Lumary CEO

Home care safeguards when disasters hit

"Historic legislation" allows authorised nurses to prescribe PBS medicines

You see what others miss

Tapping into the labour mobility market to fill ongoing workforce gaps